Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening programme: The PRECAVIR study.
HCV infection
linkage to care
migrants
screening
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
10
10
2018
revised:
16
07
2019
accepted:
26
07
2019
pubmed:
23
8
2019
medline:
21
7
2020
entrez:
22
8
2019
Statut:
ppublish
Résumé
Migration of people from HCV endemic countries is a public health issue for the French healthcare system. The PRECAVIR study focused on migrant patients and provides a multidisciplinary, patient-centred approach to treat chronic HCV-infected migrants through a systematic screening programme. Between 2007 and 2017, 101 (2.98%) out of 3386 consecutive adult migrants attending two primary healthcare settings in Créteil, France, tested positive for HCV. The median age was 44.5 years old, and 55% were women. Patients were mainly from sub-Saharan Africa, Eastern Europe and Asia. Seventy-four patients were undocumented migrants, and 25 were asylum seekers. Eighty-four (83%) patients were unaware of their serological status. All patients were offered referral to a specialist in the same setting. HCV RNA testing was performed in 88 (87%) of the patients who tested anti-HCV positive. Forty-nine (57%) were chronically infected, while 39 (43%) had an undetectable viral load. All patients were treatment-naïve. More than half of patients had access to treatment. Before 2014, thirteen patients were treated with pegylated interferon and ribavirin, and an SVR was achieved in 8 (61.5%) of them. By 2017, 17 patients had begun oral, direct-acting antiviral treatment. An SVR was achieved in 16 of 17 patients (93%). However, all patients not initially eligible for treatment were lost to follow-up. This study showed the effectiveness of a coordinated care network when anti-HCV testing, linkage to care and treatment are organized for a migrant population in the same setting as long as universal treatment makes a test and treat policy possible.
Substances chimiques
Hepatitis C Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1496-1499Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Sharma S, Carballo M, Feld JJ, Janssen H. Immigration and viral hepatitis. J Hepatol. 2015;63:515-522.
European Centre for Disease Prevention and Control. Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA. Stockholm: ECDC; 2016. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/epidemiological-assessment-hepatitis-B-and-C-among-migrants-EU-EEA.pdf.
Conférence de consensus 2002: Traitement de l’hépatite C. http://www.anaes.fr.
Prise en charge de l'hépatite C par les médicaments anti-viraux à action directe (AAD). Juin 2014. https://www.has-sante.fr/portail/upload/docs/application/pdf/201407/hepatite_c_prise_en_charge_anti_viraux_aad.pdf
Pioche C, Pelat C, Larsen C, et al. Estimation of hepatitis C prevalence in the general population, metropolitan France, 2011. Bull Epidemiol Hebd. 2016;13-14:224-229.
Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M. Lot F1, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations. PLoS ONE. 2015;10(5):e0126920.
Coppola N, Alessio L, Gualdieri L, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to Jun 2013. Euro Surveill. 2015;20(35):3009. ES.2015.20.35.30009.
Hladun O, Grau A, Esteban E, Jansa JM. Results from screening immigrants of low-income countries: data from a public primary health care. J Travel Med. 2014;21:92-98.
Micallef J, Kaldor J, Dore G. Spontaneous viral clearance following acute hepatitis C Infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34-41.
Shebl FM, El-Kamary SS, Saleh DA, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol. 2009;81(6):1024-1031.
Zhang M, Rosenberg PS, Brown DL, et al. Correlates of Spontaneous Clearance of Hepatitis C Virus among People with Hemophilia. Blood. 2006;107:892-897.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized trials. Hepatology. 2012;56(6):2039-2050.
Cooper CL, Thavorn K, Corsi DE, DJ. . Hepatitis C virus infection outcomes among immigrants to Canada: a retrospective cohort analysis. Ann Hepatol. 2017;16:720-726.
Ditah I, Al Bawardy B, Gonzalez HC, et al. Lack of health insurance limits the benefits of hepatitis C virus screening. Am J Gastroenterol. 2015;110:1126-1133.
Tait JM, Wang H, Stephens BP, et al. Multidisciplinary managed care networks - life-saving interventions for hepatitis C patients. J Viral Hepat. 2017;24:207-215.
Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment, and improves antiviral response. Liver Int. 2013;33:999-1007.
Comité interministériel pour la Santé : Priorité prévention. https://solidarites-santegouv.fr/IMG/pdf/180326-dossier_de_presse_priorite_prevention.pdf.